Results 71 to 80 of about 260,154 (263)

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, Volume 13, Issue 35, 24 June 2026.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy

British Journal of Cancer, 2020
Programmed death-ligand 1 (PD-L1) expression has been described in patients with malignant peritoneal mesothelioma (MPM), but treatment strategies utilising immune checkpoint inhibition are yet to be defined.
M. G. White, Jefree J. Schulte, Lai Xue, Y. Berger, D. Schuitevoerder, C. Vining, H. Kindler, A. Husain, K. Turaga, Oliver S. Eng   +9 more
semanticscholar   +1 more source

Malignant peritoneal mesothelioma

, 2018
Malignant mesothelioma is one of the rare disease. It is an aggressive tumor arising from the mesothelial lining of the pleura or peritoneum. In our country there is no reported data or known incidence rate.
Sayeed Bin Sharif
core   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, Volume 13, Issue 35, 24 June 2026.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Clinical and surgical outcomes of patients with peritoneal mesothelioma discussed at a monthly national multidisciplinary team video‐conference meeting

BJS Open, 2020
Peritoneal mesothelioma (PM) is a rare primary neoplasm of the peritoneum with an increasing incidence worldwide. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown promise as a treatment strategy.
A. Brandl, S. Westbrook, S. Nunn, E. Arbuthnot-Smith, J. Mulsow, Haney Youssef, N. Carr, A. Tzivanakis, S. Dayal, F. Mohamed, B. Moran, T. Cecil   +11 more
semanticscholar   +1 more source

Scrotal Peritoneal Mesothelioma on PET/CT

, 2014
Although malignant mesothelioma originating from the tunica vaginalis has been reported in the literature, direct invasion of malignant peritoneal mesothelioma to the scrotal cavity has not been described yet.

core   +1 more source

Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members

Journal of Translational Medicine, 2018
Germline mutations in the BRCA-1 associated tumor protein 1 (BAP1) increase susceptibility to mesothelioma and other cancers. We describe a patient with a family history of peritoneal mesothelioma, who developed malignant peritoneal mesothelioma at age ...
Muaiad Kittaneh, Charles Berkelhammer
doaj   +1 more source

Multicystic peritoneal mesothelioma.

The American journal of case reports, 2012
Multicystic peritoneal mesothelioma is a rare disease. It is not certain if it is a benign or a borderline tumor. Although many therapeutic approaches have been used, complete cytoreductive surgery in combination with hyperthermic intraoperative intraperitoneal chemotherapy has gained acceptance.A case of multicystic peritoneal mesothelioma in a 16 ...
Tentes, Antonios-Apostolos, Zorbas, Georgios, Pallas, Nicolaos, Fiska, Aliki   +3 more
openaire   +2 more sources

Malignant peritoneal mesothelioma

World Journal of Gastrointestinal Surgery, 2009
Malignant mesothelioma is a highly aggressive neoplasm. The incidence of malignant mesothelioma is increasing worldwide. Diffuse malignant peritoneal mesothelioma (DMPM) represents one-fourth of all mesotheliomas. Association of asbestos exposure with DMPM has been observed, especially in males.
Stine, Munkholm-Larsen, Christopher Q, Cao, Tristan D, Yan   +2 more
openaire   +2 more sources

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, Volume 13, Issue 35, 24 June 2026.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source